The news: Hims & Hers has added more weight loss treatments to its platform, including Eli Lilly’s Zepbound and Mounjaro and generic liraglutide, an older GLP-1 medication.

Hims doesn’t take insurance, meaning Zepbound and Mounjaro will cost customers $1,899 a month. Hims is also now selling Novo Nordisk’s Wegovy for $1,999/month and Ozempic for $1,799/month.

How we got here: Hims had always planned on offering Lilly’s and Novo’s branded GLP-1 weight loss drugs if there was sufficient supply.

You've read 0 of 2 free articles this month.

Get more articles - create your free account today!

Products

Events & Resources

Topics

Latest Articles

Shoppers hate paying for return shipping more than any other part of the process

Doctors expect longer visits as parents seek clarity about pediatric vaccine guidelines

Lowe’s reaches out to Gen Alpha with new rewards program for kids

Meta faces critical questions as AI spending and regulatory scrutiny intensify

J&J launches direct-to-consumer prescription drug site with lower cash prices

The health and fitness industry’s future is subscription-first, not hardware-led

Scam exposure on social platforms threatens brands

Email is consumers’ top marketing channel, but inbox fatigue threatens ROI

How payment providers should react to OpenAI’s Instant Checkout walkback

Capital One joins finance industry layoff trend, sheds 1,100 Discover workers

About

Eli Lilly’s snub of Hims could spell trouble for the D2C healthcare company’s weight loss drug business

Coverage Areas →

Coverage Areas →

Advertising & Marketing

Health

Ecommerce & Retail

Technology

Financial Services

More Topics

Geographies

EMARKETER

Media Services

Free Content

Contact Us →

Worldwide HQ

Sales Inquiries